ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,164.13
0.53%
Dow Jones
39,331.85
0.41%
Gold vs US Dollar
2,346.06
0.68%
Brent Oil
86.06
-0.45%
Bitcoin
60,126.86
-3.06%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Apogee Therapeutics Inc (APGE)

  7. Apogee Therapeutics Inc (APGE) News

Apogee Therapeutics (APGE)

Apogee Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:APGE
DateTimeSourceHeadlineSymbolCompany
08/06/202401:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APGEApogee Therapeutics Inc
07/06/202421:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APGEApogee Therapeutics Inc
31/05/202401:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APGEApogee Therapeutics Inc
31/05/202401:05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:APGEApogee Therapeutics Inc
28/05/202412:36Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:APGEApogee Therapeutics Inc
28/05/202412:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APGEApogee Therapeutics Inc
28/05/202412:30GlobeNewswire Inc.Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MDNASDAQ:APGEApogee Therapeutics Inc
23/05/202412:30GlobeNewswire Inc.Apogee Therapeutics to Participate in Upcoming June Investor ConferencesNASDAQ:APGEApogee Therapeutics Inc
15/05/202421:01GlobeNewswire Inc.Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory DiseasesNASDAQ:APGEApogee Therapeutics Inc
13/05/202412:26Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:APGEApogee Therapeutics Inc
13/05/202412:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:APGEApogee Therapeutics Inc
13/05/202412:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APGEApogee Therapeutics Inc
13/05/202412:00GlobeNewswire Inc.Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial ResultsNASDAQ:APGEApogee Therapeutics Inc
06/05/202413:00GlobeNewswire Inc.Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare ConferenceNASDAQ:APGEApogee Therapeutics Inc
25/03/202411:00GlobeNewswire Inc.Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory DiseasesNASDAQ:APGEApogee Therapeutics Inc
12/03/202420:01GlobeNewswire Inc.Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 MillionNASDAQ:APGEApogee Therapeutics Inc
11/03/202410:01Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:APGEApogee Therapeutics Inc
08/03/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:APGEApogee Therapeutics Inc
07/03/202423:49GlobeNewswire Inc.Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public OfferingNASDAQ:APGEApogee Therapeutics Inc
07/03/202423:27Edgar (US Regulatory)Form S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)]NASDAQ:APGEApogee Therapeutics Inc
05/03/202421:23GlobeNewswire Inc.Apogee Therapeutics, Inc. Announces Proposed Underwritten Public OfferingNASDAQ:APGEApogee Therapeutics Inc
05/03/202421:05Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:APGEApogee Therapeutics Inc
05/03/202413:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APGEApogee Therapeutics Inc
05/03/202411:15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:APGEApogee Therapeutics Inc
05/03/202411:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APGEApogee Therapeutics Inc
05/03/202411:10GlobeNewswire Inc.Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:APGEApogee Therapeutics Inc
05/03/202411:00GlobeNewswire Inc.Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of SchNASDAQ:APGEApogee Therapeutics Inc
04/03/202421:01GlobeNewswire Inc.Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024NASDAQ:APGEApogee Therapeutics Inc
02/01/202412:30GlobeNewswire Inc.Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:APGEApogee Therapeutics Inc
21/12/202301:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APGEApogee Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:APGE

Your Recent History

COIN
DFCCUST
BIT
F16275
Vontobel Financial Produ...
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved